ASPIRE
Who is this for?
Those with refractory or unexplained chronic cough (cough ≥ 8 weeks)
Study:
This study looks at the drug taplucainium as an inhalation powder. It aims to compare different dosages of the drug on its effectiveness at reducing cough.